RetinalGenix Technologies contracts Seer Bio to advance early detection of neurodegenerative systemic and retinal diseases
RetinalGenix Technologies Inc. has contracted Seer, Inc. to enhance early detection of neurodegenerative and retinal diseases. The collaboration will integrate RetinalGenix’s retinal imaging technology with Seer’s proteomic profiling platform to identify biomarkers for conditions like Alzheimer’s, Parkinson’s, and diabetic retinopathy. The partnership aims to accelerate diagnostic innovation and broaden early-detection solutions in clinical and home care settings.
RetinalGenix Technologies Inc. announced that it has entered into a contract with Seer, Inc., a life sciences company, to collaborate on early detection of neurodegenerative, systemic, and retinal diseases. The agreement involves integrating RetinalGenix’s ultra-high-resolution retinal imaging technology with Seer’s proteomic profiling platform to identify novel biomarkers for earlier detection and improved monitoring of conditions such as Alzheimer’s disease, Parkinson’s disease, diabetic retinopathy, and cardiovascular diseases. The collaboration includes research, development, and clinical validation programs aimed at accelerating diagnostic innovation and enabling broader deployment of early-detection solutions in clinical and home-based care settings. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RetinalGenix Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9546622-en) on October 16, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
